Tsfg LLC Sells 1,139 Shares of CVS Health Corporation $CVS

Tsfg LLC cut its stake in shares of CVS Health Corporation (NYSE:CVS) by 6.8% in the 2nd quarter, HoldingsChannel reports. The fund owned 15,548 shares of the pharmacy operator’s stock after selling 1,139 shares during the quarter. Tsfg LLC’s holdings in CVS Health were worth $1,073,000 as of its most recent filing with the Securities & Exchange Commission.

Several other institutional investors and hedge funds also recently made changes to their positions in the company. Silver Oak Securities Incorporated acquired a new position in CVS Health in the 1st quarter valued at $292,000. Brookstone Capital Management boosted its position in shares of CVS Health by 5.0% in the first quarter. Brookstone Capital Management now owns 72,895 shares of the pharmacy operator’s stock valued at $4,939,000 after acquiring an additional 3,475 shares during the period. Capital Investment Advisory Services LLC grew its stake in shares of CVS Health by 12.8% in the first quarter. Capital Investment Advisory Services LLC now owns 16,031 shares of the pharmacy operator’s stock valued at $1,086,000 after acquiring an additional 1,815 shares in the last quarter. Wayfinding Financial LLC bought a new position in CVS Health during the first quarter worth about $54,000. Finally, Bank of New York Mellon Corp raised its stake in CVS Health by 2.1% in the 1st quarter. Bank of New York Mellon Corp now owns 8,981,262 shares of the pharmacy operator’s stock worth $608,481,000 after purchasing an additional 183,813 shares in the last quarter. Institutional investors and hedge funds own 80.66% of the company’s stock.

CVS Health Price Performance

CVS Health stock opened at $78.13 on Monday. The stock has a fifty day moving average of $76.49 and a 200-day moving average of $69.04. The stock has a market capitalization of $99.18 billion, a P/E ratio of 205.61, a price-to-earnings-growth ratio of 0.87 and a beta of 0.60. The company has a debt-to-equity ratio of 0.83, a quick ratio of 0.62 and a current ratio of 0.83. CVS Health Corporation has a 52 week low of $43.56 and a 52 week high of $85.15.

CVS Health (NYSE:CVS) last released its earnings results on Wednesday, October 29th. The pharmacy operator reported $1.60 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $1.36 by $0.24. The firm had revenue of $102.87 billion for the quarter, compared to analysts’ expectations of $98.85 billion. CVS Health had a return on equity of 11.45% and a net margin of 0.12%.The business’s revenue for the quarter was up 7.8% on a year-over-year basis. During the same quarter in the previous year, the business posted $1.09 earnings per share. CVS Health has set its FY 2025 guidance at 6.550-6.650 EPS. On average, sell-side analysts expect that CVS Health Corporation will post 5.89 earnings per share for the current fiscal year.

CVS Health Dividend Announcement

The business also recently disclosed a quarterly dividend, which will be paid on Monday, November 3rd. Investors of record on Thursday, October 23rd will be paid a $0.665 dividend. The ex-dividend date of this dividend is Thursday, October 23rd. This represents a $2.66 annualized dividend and a yield of 3.4%. CVS Health’s dividend payout ratio is presently 700.00%.

Insiders Place Their Bets

In other CVS Health news, Director Anne A. Finucane sold 7,500 shares of the business’s stock in a transaction on Wednesday, August 20th. The shares were sold at an average price of $71.02, for a total transaction of $532,650.00. Following the sale, the director owned 22,156 shares of the company’s stock, valued at approximately $1,573,519.12. The trade was a 25.29% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which can be accessed through the SEC website. 1.22% of the stock is owned by corporate insiders.

Analysts Set New Price Targets

A number of brokerages have issued reports on CVS. Leerink Partners increased their target price on shares of CVS Health from $86.00 to $95.00 and gave the stock an “outperform” rating in a research report on Thursday, October 16th. Wolfe Research boosted their price target on CVS Health from $80.00 to $85.00 and gave the company an “outperform” rating in a research note on Monday, September 22nd. Bernstein Bank lowered their price objective on CVS Health from $78.00 to $72.00 and set a “market perform” rating on the stock in a research note on Wednesday, July 16th. Wall Street Zen downgraded CVS Health from a “buy” rating to a “hold” rating in a research report on Saturday. Finally, Barclays increased their target price on CVS Health from $80.00 to $87.00 and gave the stock an “overweight” rating in a report on Thursday, September 4th. Two research analysts have rated the stock with a Strong Buy rating, twenty have given a Buy rating and four have assigned a Hold rating to the company’s stock. According to MarketBeat.com, CVS Health currently has an average rating of “Moderate Buy” and an average target price of $87.91.

About CVS Health

CVS Health Corporation provides health solutions in the United States. It operates through Health Care Benefits, Health Services, and Pharmacy & Consumer Wellness segments. The Health Care Benefits segment offers traditional, voluntary, and consumer-directed health insurance products and related services.